# **BMJ Open** Development of a risk prediction tool for patients with locally advanced and recurrent rectal cancer undergoing pelvic exenteration: protocol for a mixed-methods study

Kilian Brown <sup>(b)</sup>, <sup>1,2,3,4</sup> Michael Solomon, <sup>1,2,3,4</sup> Kheng-Seong Ng, <sup>1,2,3,4,5</sup> Paul Sutton, <sup>6,7</sup> Cherry Koh, <sup>1,2,3,4</sup> Kate White <sup>(b)</sup>, <sup>8,9</sup> Daniel Steffens, <sup>2,4</sup> EviSurg Research Group

### ABSTRACT

**To cite:** Brown K, Solomon M, Ng K-S, *et al.* Development of a risk prediction tool for patients with locally advanced and recurrent rectal cancer undergoing pelvic exenteration: protocol for a mixedmethods study. *BMJ Open* 2023;**13**:e075304. doi:10.1136/ bmjopen-2023-075304

Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2023-075304).

Received 04 May 2023 Accepted 18 August 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

**Correspondence to** Dr Kilian Brown; kilian.brown@sydney.edu.au

Introduction Pelvic exenteration (PE) surgery represents the only potentially curative treatment option for patients with locally advanced or recurrent rectal cancer (LARRC). Given the potential morbidity, whether or not PE should be recommended for an individual patient presents a major decisional conflict. This study aims to identify the outcomes of PE for which there is consensus among patients, carers and clinicians regarding their importance in guiding treatment decision-making, and to develop a risk prediction tool which predicts these outcomes. Methods and analysis This study will be conducted at a specialist PE centre, and employ a mixed-methods study design, divided into three distinct phases. In phase 1, outcomes of PE will be identified through a comprehensive systematic review of the literature (phase 1a), followed by exploration of the experiences of individuals who have undergone PE for LARRC and their carers (phase 1b, target sample size 10-20 patients and 5-10 carers). In phase 2, a survey of patients, their carers and clinicians will be conducted using Delphi methodology to explore consensus around the outcomes of highest priority and the level of influence each outcome should have on treatment decision-making. In phase 3 a, risk prediction tool will be developed using data from a single PE referral centre (estimated sample size 500 patients) to predict priority outcomes using multivariate modelling, and externally validated using data from an international PE collaboration.

**Ethics and dissemination** Ethical approval has been granted for phases 1 and 2 (X22-0422 and 2022/ ETH02659) and for maintenance of the database used in phase 3 (X13-0283 and HREC/13/RPAH/504). Informed consent will be obtained from participants in phases 1b and 2; a waiver of consent for secondary use of data in phase 3 will be sought. Study results will be submitted for publication in international and/or national peer reviewed journals.

PROSPERO registration number CRD42022351909.

# STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ Define priority outcomes of pelvic exenteration according to individuals who have undergone surgery, their carers and clinicians.
- ⇒ Develop a risk prediction tool using prospective individual patient data from a high-volume centre.
- ⇒ External validation using international, multicentre data.
- ⇒ Potential limited generalisability beyond highvolume, specialist centres.

### INTRODUCTION

Pelvic exenteration (PE) surgery represents the standard of care for selected patients presenting with locally advanced or recurrent rectal cancer, and the only poten-≥ tially curative treatment option.<sup>1</sup> This ultraradical surgical procedure involves en bloc resection of all anatomical strucĝ tures contiguously involved by tumour, and typically requires excision of multiple pelvic viscera as well as pelvic bone and major neurovascular structures, followed by complex reconstruction. Refinement of surgical techniques in recent decades has made increasingly radical 'higher and wider' resections in all compartments of **D** the pelvis safe and oncologically feasible.<sup>23</sup> However, such radical surgery may be associated with major morbidity (32%-38%),<sup>4-6</sup> functional impairment,<sup>7</sup> at least a temporary reduction in quality of life,<sup>8</sup> as well as substantial cost to the healthcare system.<sup>9</sup> Therefore, whether or not radical surgery should be recommended for an individual patient with locally advanced or recurrent rectal cancer presents a major decisional conflict for the team of treating clinicians,

to text

t and

Protected by copyright, including for uses related



where the consequences of surgery must be weighed against the potential for cure. The paradigm has shifted such that the decision to be made is no longer what can be technically resected, but rather what should be.<sup>10</sup>

Currently, the decision-making process around whether curative intent PE surgery is recommended for an individual patient tends to be based on individual clinician and centres' experiences, rather than a reproducible, evidence-based process. This may lead to substantial variation in treatment decision-making within and between PE centres, as has been recently demonstrated by international comparative data,<sup>11</sup> as well as variation in which patients with a new diagnosis of locally advanced or recurrent rectal cancer are referred to a PE centre for consideration of potentially curative surgery. Recommendations for or against surgery, and decisions around whether to refer a patient to a PE centre, are often made with survival as the primary outcome of interest, and which other outcomes of surgery (such as anticipated quality of life, functional outcomes and morbidity) are considered important by patients, carers and clinicians and how they should be incorporated into the decisionmaking process is not well understood.

This study aims to develop a risk prediction tool to predict the outcomes of PE that are considered most important by patients with locally advanced and recurrent rectal cancer, their carers and clinicians. The tool may be used at the time of diagnosis by referring clinicians, as well as those managing patients at a specialist PE centre, to access an evidence-based prediction of the anticipated outcomes of surgery for an individual patient. Development and implementation of this tool will assist clinicians to navigate the decisional conflict



Figure 1 Schematical representation for the development of the pelvic exenteration risk prediction tool. \*Hypothesised priority outcomes are listed. Actual outcomes will be identified during phases 1 & 2.

COS methodology will be modified to account for this different objective.

There will be three distinct phases of this study. In phase 1, outcomes of PE will be identified through a comprehensive systematic review of the literature (phase 1a), followed by in depth exploration of experiences of individuals who have undergone PE for locally advanced or recurrent rectal cancer and their carers using qualitative research framework (phase 1b). In phase 2, a survey of individuals who have undergone PE, carers and clinicians will be conducted using the Delphi methodology to explore consensus around the outcomes of highest priority and the level of influence each outcome should have on treatment decision-making. In phase 3, a risk prediction tool will be developed to predict the identified priority outcomes using comprehensive multivariate modelling.

### Multidisciplinary advisory committee

This study will be governed by a multidisciplinary advisory committee (MAC), which will comprise of cancer specialists (surgeons, medical and radiation oncologists, senior surgical and cancer nurses, allied health professionals), a health economist, statistician, epidemiologist, health policymaker, guideline and quality measurement developer, information technology professional, patients and carers. The MAC will guide development of the tool and in later phases (beyond those outlined in this protocol) advise on development of a surgical decision-making tool, which produces a recommendation for or against PE surgery based on the risk prediction model developed in this study. The MAC will also develop communication strategies and guide translation to clinical practice with implementation and long-term sustainability plans.

### Patient and public involvement

Two consumers have been consulted during the development of the study concept and protocol. Individuals who have undergone PE and their nominated carer/ family member will inform the development of PE priority outcomes through in-depth interviews (phase 1). The interviews will explore their experience of PE, the decision-making process and identify priorities and factors that informed the decision. Both are included as participant groups in the Delphi process (phase 2). One or more consumers will be members of the advisory group involved in reviewing the outcomes identified in phase 1 prior to those outcomes being distributed in the subsequent Delphi study.

## Phase 1: identifying outcomes of PE Phase 1a

This phase aims to identify all outcomes of PE for locally advanced or recurrent rectal cancer reported in the published literature. The review will be conducted according to the Cochrane Collaboration guidelines<sup>15</sup> and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.<sup>16</sup> A comprehensive search strategy has been created in conjunction with an experienced medical librarian. The protocol has been published a priori on the PROSPERO registry.<sup>17</sup>

MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Cumulative Index to Nursing & Allied Health Literature (CINAHL) and Scopus were searched from 1990 to 25 April 2023 for combinations of the following medical subject headings and keywords: pelvic exenteration or extended radical resection or multivisceral resection, and rectal neoplasms. The search was limited to studies published from 1990 onward, English language and adult patient. The complete search strategies are available in online supplemental file 1.

Retrospective and prospective cohort studies, crosssectional studies, qualitative studies and randomised trials reporting outcomes of PE or multivisceral resection as the primary treatment for locally advanced or recurrent adenocarcinoma of the rectum will be included. Studies will be excluded if >10% of the population had non-rectal cancers or underwent less extensive resection and outcomes were not reported separately. Narrative reviews, case reports, case series including <5 patients, conference abstracts and letters will be excluded.

Abstracts will be screened by two reviewers independently and one reviewer will complete the full text screening and data extraction, with all extracted outcomes then reviewed by a multidisciplinary team. Data (all verbatim outcomes and their definitions) will be extracted and entered into an electronic database using a custom-designed data entry form. Outcomes will be merged with similar outcomes using different  $\Xi$ wording to create 'standardised outcomes' and allocated to a domain, each of which will be reviewed at a multi-≥ disciplinary advisory meeting, attended by specialist clinitraining, and cians and nurses, a surgical outcomes researcher, and two patient advocates.

# Phase 1b

In this phase, an exploratory qualitative interpretive design will be used to investigate the perspectives of individuals who have undergone PE and their carers on the important outcomes of surgery for them individually. Individual interviews with people who have undergone PE and their carers will be conducted using opened semistructured interview format to maintain a participant-led dialogue. Two topic frameworks have 8 been developed-for individuals who have undergone PE and for carers (online supplemental file 2). The interviews will aim to identify all outcome following PE which the participant considers important, by exploring the general experience of the individual who underwent PE, which information they did or did not access about PE, alternative treatments at the time of diagnosis, how the patient decided whether or not to undergo PE, how having undergone PE has

Purposive sampling criteria to guide recruitment in Table 1 phase 1b

Characteristics	Target no of participants
Age at surgery	
<50 years	5–8
≥ 50 years	5–8
Sex	
Male	5–8
Female	5–8
Place of residence	
Local (metropolitan Sydney)	6–10
Rural/regional	4–5
Tumour	
Locally advanced primary rectal cancer	5–8
Locally recurrent rectal cancer	5–8
Total sample	10–20

impacted their life, and which factors they would view as most important if counselling someone about undergoing PE.

### Participants, recruitment and setting

Individuals who have undergone PE for locally advanced or recurrent rectal cancer at Royal Prince Alfred Hospital, Sydney, Australia, will be identified from a prospectively maintained electronic PE database and invited to participate. The inclusion criteria are outlined below. The final sample size will be determined by iterative analysis for data saturation, with an estimated sample size required for saturation of 10-20 patients and 5-10 carers. A purposive sampling matrix was developed (table 1) to guide recruitment and in order to ensure the participants represent a broad group of individuals with diverse views. Characteristics used for selection will include age at time of surgery, gender, place of residence and tumour type. Carers for individuals who have undergone PE will also be invited to participate. According to participant preference, interviews will take place face to face or via telephone.

Inclusion criteria

- Adults  $\geq 18$  years of age.
- Patients who have undergone PE for locally advanced or locally recurrent rectal cancer.
- Patients who are more than 6 months post PE surgery.
- Patients who are fit to participate in an interview (according to their treating clinician).
- Patients who are able to participate in an interview in English.
- Patients who have the capacity to provide informed consent.
- The nominated carer for a participating individual who has undergone PE. This may be a spouse, child or other close relative. Paid carers or those from a support agency will not be included.

# BMJ Open: first published as 10.1136/bmjopen-2023-075304 on 30 August 2023. Downloaded Enseignement Superieur from http://bmjopen.bmj.com/ on June 9, 2025 at Agence Bibliographique de I

# Data collection and analysis

Baseline demographic characteristics of participating individuals will be extracted from the existing PE database. Interviews will be audiorecorded, transcribed verbatim and imported into NVivo qualitative analysis software (NVivo V.11, OSR International, Burlington, Massachusetts, USA). Template analysis will be used to analyse the interview content, where outcomes of PE identified in the interview transcripts will be coded using NVivo and themes will be identified. Coded data will be Protected by copy used to generate a list of outcomes of PE which are prioritised by patients and carers.

### Participant consent and withdrawal

All participants will complete a consent form after they have read the approved participant information sheet and had time to consider participation, and consent will be confirmed verbally at the start of the interview. Participants will be able to take a break, end the interview or withdraw from the study at any time, without any impact on their relationship with their treating clinician(s) or ing hospital. for uses re

### Phase 2: defining priority outcomes by consensus

Outcomes identified from the literature and interviews in phase 1 will be reviewed according to the method described by Fish et al.<sup>12</sup> 'Standardised outcome terms' will be developed, where outcomes which have the same G meaning but are described with different wording are combined. Similar standardised outcomes will then be grouped by domain. Standardised outcome terms and a domains for each outcome will be ratified at an MAC subcommittee meeting, attended by cancer specialists, an academic with experience in surgical outcomes, senior PE nursing staff and consumer advocates. Outcomes will be excluded if considered to be of minimal clinical relevance by the MAC subcommittee. The resulting list of standardised outcomes will be used to populate the first of a three round iterative survey process using Delphi methodology.<sup>18</sup>

### Participants, recruitment and setting

and simi Participants will be recruited from three key participant groups:

- Clinicians with experience in PE and the management of locally advanced and recurrent rectal cancer (including medical, nursing and allied health staff). Clinicians will be identified via the International PelvEx Collaborative (an international collaborative group made up of specialist surgeons/physicians with experience managing advanced pelvic cancer) and Australia and New Zealand Pelvic Exenteration Multi-Disciplinary teams.
- Patients who have undergone PE for locally advanced primary or recurrent rectal cancer. Patients will be identified from an existing institutional PE database as for phase 1.

Carers for patients who have undergone PE for locally advanced primary or recurrent rectal cancer. Patients who participate will be asked to forward the invitation email to their carers.

Identified potential participants will be initially contacted via email to advise of the upcoming Delphi survey and provide a study information sheet. The first round of the survey will be emailed 5 days after the initial contact, followed by reminders at 10 and 20 days. Following the final reminder, non-responders will be excluded from the study. Late replies will be considered, if within the study time frame. The second and the third rounds of the survey will be emailed to all responders of the survey first round. The same reminder protocol will be used. The survey rounds will be approximately 30 days apart. Snowball sampling will be used where all participants will be invited to forward the first round invitation email to anyone who is eligible to participate.

# Data collection and analysis

Survey first round: Participants will indicate whether they are a patient, carer or clinician, which will allow them to access a survey specifically designed for each of these participant groups. The first round of the survey will be divided into two main sections:

- Section 1 will include demographic information specific to each participant group:
  - Patients: age, gender, tumour type (primary or recurrent rectal), months since surgery.
  - Carers: age, gender, relationship to patient with locally advanced or recurrent rectal cancer.
  - Clinicians: age group, gender, specialty, qualifications, whether a dedicated PE fellowship was undertaken, country of residency, number of years of experience treating locally advanced and recurrent rectal cancer, whether they practice within a dedicated pelvic oncology multidisciplinary team, the number of operations performed annually (in the case of surgeons).
- Section 2 will present participants with the outcomes identified in the systematic review and interviews, grouped by domains. Participants will be asked to use a 9-point Likert scale to rate the importance of each outcomes as limited importance<sup>1-3</sup>; important but not critical<sup>4-6</sup> and critically important.<sup>7-9</sup><sup>14</sup> An open question will be included at the end of the survey to allow participants to list any additional outcomes that they do not feel have been identified or considered in the questionnaire. Each outcome will be described in medical (for clinicians) and lay terms (for patients and carers).

Survey second round: In round 2, a list of all outcomes with a mean score or 4–6 (important but not critical) and 7-9 (critically important) during round 1 will be collated with any additional unique outcomes suggested by participants and redistributed (those scoring 1-3 will be discarded). Participants will be provided with feedback from round 1 in the form of their previous score for each

domain and a mean score from their participant group. Participants will be asked to reflect on the information presented before scoring each outcome again on the 9-point Likert scale.

Consensus around outcomes will be assessed prior to round 3, where consensus status for each outcome will be categorised according to Williamson *et al*<sup>19</sup> as:

- 1. Consensus in: 70% or more respondents within a participant group rate the outcome as critically important<sup>7-9</sup> and 15% or fewer rate the outcome as limited  $\underline{r}$
- importance.<sup>1–3</sup> Consensus out: 70% or more of respondents within a participant group rate the outcome as limited impor-2. Consensus out: 70% or more of respondents within a ş tance and 15% or fewer rate the outcome as critically important.7-9
- 3. No consensus: Neither of the above criteria are met.

copyrig Survey third round: In this final round, the refined list of 'consensus in' outcomes will be included. Participants will be asked to divide 100 points among the 'consensus in' outcomes according to the relative level of influence each outcome should have on treatment decision-making. The outcomes will be listed in rank order based on the mean number of points attributed to each. This list will form the provisional list of priority outcomes.

Descriptive statistics will be used to characterise the participants according to participant group. Means and SD will be used to rank the outcomes. The data from all rounds will be displayed in descriptive format, with mean responses, in order of overall ranking of importance.

# Participant consent

All invited participants have no obligation to complete the study surveys and can withdraw from the study at any time. Completion of the study survey will be an indication of implied consent.

# Phase 3: predicting priority outcomes

text and data mining, Al train This phase aims to develop a risk prediction model, which can be used at the time of diagnosis to predict each priority outcome (identified in phase 2) for individual patients using information available at the time of treatment decision. An MAC subcommittee will review and ratify the provisional list of priority outcomes prior to this phase of the study.

# Participants, recruitment and setting

Patients who underwent PE for locally advanced primary or recurrent rectal cancer at Royal Prince Alfred Hospital, Sydney, Australia between 1994 and 2023 will be identified from the authors' institutional PE database. This database is prospectively maintained and includes extensive preoperative, intraoperative, postoperative, long-term survival and quality of life data. The estimated number of eligible patients is 500.

# Preoperative variables

Preoperative variables to be used to calculate patientspecific risk scores for each of the priority outcomes will be selected from the PE database based on demonstrable predictive value and face validity according to expert opinion. Due to the design of this study, preoperative variables cannot be selected a priori as the priority outcomes to be predicted will not be identified until the end of phase 2. If required, multiple imputation will be used for missing values.

### Data collection and analysis

For eligible patients, priority outcome data (eg, survival, quality of life, complication rate) and all potential preoperative risk factors for those outcomes (eg, demographics, comorbidities and tumour factors) will be extracted from the PE database. Using this individual patient data, risk prediction models for each of the priority outcomes of PE will be developed. An experienced biostatistician will be involved in conducting and interpreting these analyses. Two main approaches will be used, including traditional multivariate regression techniques and machine learning approaches. The accuracy of the models will be compared by the computed sensitivity, specificity, negative predictive value, positive predictive value, accuracy and area under the curve. A separate statistical analysis plan will be developed for internal validation and external validation (using Australian wide and international individual patient data via the International PelvEx Collaborative Group).

### ETHICS AND DISSEMINATION

Phase 1 involves a systematic review of the literature, semistructured interviews with patients and their carers, and a Delphi survey study of clinicians, patients and carers. Ethics approval for phase 1 has been granted by the Sydney Local Health District HREC (X22-0422 and 2022/ ETH02659). Ethics approval for the Pelvic Exenteration Quality Improvement database, which will be used for the statistical modelling in phase 2, is current (X13-0283 and HREC/13/RPAH/504). Other than the patients/carer interviews and Delphi survey, where the risk to the participant is that of inconvenience or distress, this project is observational and does not involve any therapeutic intervention. Therefore, there are no other potentially ethically adverse consequences. Informed consent will be obtained from participants in phases 1b and 2; a waiver of consent for secondary use of data in phase 3 will be sought prior to commencement of phase 3.

The results of this study will be submitted for publication in scientific journals and for presentation at scientific meetings.

Beyond phase 3, future investigation will focus on development of a surgical decision-making tool which produces a patient-specific recommendation for or against PE, in a reproducible fashion. This recommendation will be based on the predicted priority outcomes for an individual patient according to the risk prediction model developed in the current study. This will involve using consensus methods among experts to define the threshold values for the predicted priority outcomes at which a recommendation for or against surgery is made.

### Study status and planned timeline

Phase 1a: January 2023–September 2023 (manuscript under peer review).

Phase 1b: May 2023–November 2023 (data collection underway).

Phase 2: December 2023–April 2024 (not commenced). Phase 3: May 2024–December 2024 (not commenced).

### Author affiliations

<sup>1</sup>Department of Colorectal Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

<sup>2</sup>Surgical Outcomes Research Centre (SOuRCe), Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

<sup>3</sup>Institute of Academic Surgery (IAS), Royal Prince Alfred Hospital, Sydney, New South Wales, Australia

<sup>4</sup>Faculty of Medicine and Health, Central Clinical School, The University of Sydney, Sydney, New South Wales, Australia

<sup>5</sup>Department of Colorectal Surgery, Concord Repatriation General Hospital, Sydney, New South Wales, Australia

 $^{\rm 6}{\rm Colorectal}$  & Peritoneal Oncology Centre, The Christie NHS Foundation Trust, Manchester, UK

<sup>7</sup>Division of Cancer Sciences, The University of Manchester, Manchester, UK
<sup>8</sup>Sydney Nursing School, University of Sydney, Sydney, New South Wales, Australia
<sup>9</sup>The Daffodil Centre, University of Sydney and Cancer Council NSW, Sydney, New South Wales, Australia

### Twitter Daniel Steffens @SOuRCe\_RPA

**Collaborators** The EviSurg Research Group: Dr Nabila Ansari, Dr Wendy Brown, Professor Phyllis Butow, A/Professor Sharon Carey, Dr Alix Dumitrescu, Professor Lisa Horvath, A/Professor Kate Mahon, Dr Kate McBride, Professor Glen Salkeld, A/ Professor Charbel Sandroussi, Professor Des Winter, Dr David Yeo, Professor Jane Young.

**Contributors** All authors made significant contributions to the design and development of this study and achieving ethical approval. KB was a major contributor in writing this paper. MS, DS, K-SN, PS, CK and KW contributed to the drafting and editing of this paper and approved the final manuscript.

**Funding** KB is the recipient of the Mitchell J Notaras Fellowship in Colorectal Surgery from the University of Sydney. This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

# 6

# Open access

BMJ Open: first published as 10.1136/bmjopen-2023-075304 on 30 August 2023. Downloaded from http://bmjopen.bmj.com/ on June 9, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

### **ORCID** iDs

Kilian Brown http://orcid.org/0000-0003-0967-8515 Kate White http://orcid.org/0000-0003-4763-1734

### REFERENCES

- 1 Brown KGM, Solomon MJ, Koh CE. Pelvic exenteration surgery: the evolution of radical surgical techniques for advanced and recurrent pelvic malignancy. *Dis Colon Rectum* 2017;60:745–54.
- Solomon MJ. Redefining the boundaries of advanced pelvic oncology surgery. *Br J Surg* 2021;108:453–5.
- 3 Harji DP, Griffiths B, McArthur DR, et al. Surgery for recurrent rectal cancer: higher and wider Colorectal Dis 2013;15:139–45.
- 4 PelvEx Collaborative. Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer. *Br J Surg* 2018;105:650–7.
- 5 Collaborative P. Surgical and survival outcomes following pelvic exenteration for locally advanced primary rectal cancer: results from an international collaboration. *Ann Surg* 2019;269:315–21.
- 6 Venchiarutti RL, Solomon MJ, Koh CE, et al. Pushing the boundaries of pelvic exenteration by maintaining survival at the cost of morbidity. Br J Surg 2019;106:1393–403.
- 7 Makker PGS, Koh CE, Solomon MJ, et al. Functional outcomes following pelvic exenteration: results from a prospective cohort study. *Colorectal Dis* 2021;23:2647–58.
- 8 Steffens D, Solomon MJ, Young JM, et al. Cohort study of long-term survival and quality of life following pelvic exenteration. *BJS Open* 2018;2:328–35.
- 9 Koh CE, Badgery-Parker T, Salkeld G, et al. Cost-effectiveness of pelvic exenteration for locally advanced malignancy. Br J Surg 2016;103:1548–56.

- 10 Solomon MJ, Brown KGM. Extended radical resection: the standard of care for patients with advanced pelvic malignancy. *Ann Surg Oncol* 2020;27:323–4.
- 11 Denost Q, Solomon M, Tuech J-J, et al. International variation in managing locally advanced or recurrent rectal cancer: prospective benchmark analysis. Br J Surg 2020;107:1846–54.
- 12 Fish R, Sanders C, Williamson PR, et al. Core outcome research measures in anal cancer (CORMAC): protocol for systematic review, qualitative interviews and Delphi survey to develop a core outcome set in anal cancer. BMJ Open 2017;7:e018726.
- 13 Fish R, Sanders C, Adams R, et al. A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus. Lancet Gastroenterol Hepatol 2018;3:865–73.
- 14 Williamson PR, Altman DG, Bagley H, *et al*. The COMET handbook: version 1.0. *Trials* 2017;18:280.
- 15 Cochrane Handbook for systematic reviews of interventions. 2 Ed. Chichester (UK) John Wiley & Sons; 2019.
- 16 Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006–12.
- 17 Brown KGM, Pisaniello J, Ng KS, et al. Systematic review of outcomes measured and reported in studies of pelvic exenteration for the treatment of locally advanced and recurrent rectal cancer. PROSPERO CRD42022351909. 2022. Available: https://www.crd. york.ac.uk/prospero/display\_record.php?ID=CRD42022351909
- 18 Jünger S, Payne SA, Brine J, et al. Guidance on conducting and reporting Delphi studies (CREDES) in palliative care: recommendations based on a methodological systematic review. *Palliat Med* 2017;31:684–706.
- 19 Williamson PR, Altman DG, Blazeby JM, et al. Developing core outcome sets for clinical trials: issues to consider. *Trials* 2012;13:132.

# MEDLINE SEARCH STRATEGY

- 1. Pelvic Exenteration/
- 2. (pelvi\* and exent\*).mp.
- 3. pelvic clearance.mp.
- 4. extended resection\*.mp.
- 5. extended radical resection\*.mp.
- 6. (salvage adj2 (surger\* or resect\* or excis\*)).mp.
- 7. ((multi?visceral or multi?organ) adj2 (surger\* or resect\* or excis\*)).mp.
- 8. 1 or 2 or 3 or 4 or 5 or 6 or 7
- 9. Rectal Neoplasms/

10. ((rectal or rectum) adj2 (neoplas\* or cancer\* or tumour\* or tumor\* or malignan\* or carcinom\* or adenocarcinoma\* or recurren\* or regrowth or mass)).mp.

- 11. 9 or 10
- 12. 8 and 11
- 13. limit 12 to (english language and yr="1990 -Current")

# EMBASE SEARCH STRATEGY

- 1. pelvis exenteration/
- 2. (pelvi\* and exent\*).mp.
- 3. pelvic clearance.mp.
- 4. extended resection\*.mp.
- 5. extended radical resection\*.mp.
- 6. (salvage adj2 (surger\* or resect\* or excis\*)).mp.
- 7. ((multi?visceral or multi?organ) adj2 (surger\* or resect\* or excis\*)).mp.
- 8. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
- 9. rectum tumor/
- 10. exp rectum cancer/
- 11. rectum carcinoma/

12. ((rectal or rectum) adj2 (neoplas\* or cancer\* or tumour\* or tumor\* or malignan\* or carcinom\* or adenocarcinoma\* or recurren\* or regrowth or mass)).mp.

- 13. 9 or 10 or 11 or 12
- 14. 8 and 13
- 15. limit 14 to (english language and yr="1990 -Current")

# COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS SEARCH STRATEGY

- 1. Pelvic Exenteration/
- 2. (pelvi\* and exent\*).mp.
- 3. pelvic clearance.mp.
- 4. extended resection\*.mp.
- 5. extended radical resection\*.mp.
- 6. (salvage adj2 (surger\* or resect\* or excis\*)).mp.
- 7. ((multi?visceral or multi?organ) adj2 (surger\* or resect\* or excis\*)).mp.
- 8. 1 or 2 or 3 or 4 or 5 or 6 or 7
- 9. Rectal Neoplasms/

10. ((rectal or rectum) adj2 (neoplas\* or cancer\* or tumour\* or tumor\* or malignan\* or carcinom\* or adenocarcinoma\* or recurren\* or regrowth or mass)).mp.

- 11. 9 or 10
- 12. 8 and 11
- 13. limit 12 to (english language and yr="1990 -Current")

# CINAHL SEARCH STRATEGY

S1. (MH "Pelvic Exenteration")

- S2. "pelvic exenteration\*"
- S3. (pelvi\* and exent\*)
- S4. "pelvic clearance"
- S5. "extended resection\*"
- S6. "extended radical resection\*"
- S7. (Salvage N2 (surger\* or resect\* or excis\*))
- S8. ((multi\$visceral or multi\$organ) N2 (surger\*
- or resect\* or excis\*))

S9. S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8

S10. (MH "Rectal Neoplasms+")

S11. ((rectal or rectum) N2 (neoplas\* or cancer\* or tumour\* or tumor\* or malignan\* or carcinom\* or adenocarcinoma\* or recurren\* or regrowth or mass))

S12. S10 OR S11

S13. S9 AND S12

S14. S9 AND S12 Limiters - Published Date: 19900101-20221231

S15. S9 AND S12 Narrow by Language: - english

# SCOPUS SEARCH STRATEGY

(TITLE-ABS-KEY ((pelvi\* AND exent\*) OR "pelvic clearance" OR "extended\* resection\*") OR TITLE-ABS-KEY (salvage W/2 (surger\* OR resect\* OR excis\*)) OR TITLE-ABS-KEY (((multi?visceral OR multi?organ) W/2 (surger\* OR resect\* OR excis\*)))

AND

TITLE-ABS-KEY (((rectal OR rectum) W/2 (neoplas\* OR cancer\* OR tumour\* OR tumor\* OR malignan \* OR carcinom\* OR adenocarcinoma\* OR recurren\* OR regrowth OR mass))))

AND

(LIMIT-TO (PUBYEAR, 1990 - 2022)

AND

(LIMIT-TO (LANGUAGE, "English"))

# SEMI-STRUCTURED INTERVIEW TOPIC GUIDE (CARERS)

# **Topic Guide**

Topic 1 - General experience

- Initial open-ended questions regarding their general experience caring for someone with locally advanced or recurrent rectal cancer pelvic exenteration surgery
- 'Could you tell me about your experience caring after someone with [locally advanced or recurrent] rectal cancer?'
- 'Could you tell me what it has been like to care for someone requiring major cancer surgery?'

# Topic 2 - Diagnosis

- 'Could you tell me about how you first found out your loved one had [locally advanced or recurrent] rectal cancer?
- 'What were your first thoughts when you heard the words "rectal cancer"? Had you ever heard of it before?'
- Enquire about what were they most interested to learn more about when their loved one was first diagnosed which were the post-surgical outcomes they were most interested to know about?

Topic 3 - Treatment

- Enquire how they and their loved one decided whether to undergo pelvic exenteration surgery, how involved was the carer or spouse in the decision-making process?
- Ask which information they asked for and how it impacted their decision making
- Ask about the impact surgery has/had on their loved one and their relationship, specifically prompt for physical and psychological impacts. Were these consequences expected or unexpected?
- Ask what is the most significant way that surgery has affected the carer or spouse and their relationship with their loved one? Prompt for both positive and negative impacts of surgery
- If they had to help their loved one make the decision about undergoing surgery again, which would be the most important factors to be aware of and consider?
- Ask unambiguously which outcomes of pelvic exenteration surgery are the most important when deciding whether to have surgery, and how each outcome would influence this decision

# Conclusion

• Final open ended question: 'Is there anything else that we haven't addressed that you think is important for patients with locally advanced or recurrent rectal cancer and their carers to be aware of or consider when deciding about whether to undergo surgery'?

# SEMI-STRUCTURED INTERVIEW TOPIC GUIDE (PATIENTS)

# **Topic Guide**

Topic 1 - General experience

- Initial open-ended questions regarding their general experience having locally advanced or recurrent rectal cancer and pelvic exenteration surgery
- 'Could you tell me about your diagnosis and treatment journey with [locally advanced or recurrent] rectal cancer?'
- 'Could you tell me about the surgery you underwent to treat your tumour?'

# Topic 2 - Diagnosis

- 'How did you first come to be diagnosed with [locally advanced or recurrent] rectal cancer?'
- Enquire about what were they most interested to learn more about when first diagnosed which were the post-surgical outcomes they were most interested to know about?

# Topic 3 - Treatment

- Enquire how they decided whether to undergo pelvic exenteration surgery and any other treatment options
- Ask which information they asked for and how it impacted their decision making
- Ask about the impact surgery has/had on the participant, specifically ask about physical and psychological impacts. Were these consequences expected or unexpected?
- Ask what is the most significant way that surgery has affected the patient? Prompt for both positive and negative impacts of surgery
- If they had to make the decision about undergoing surgery again, which would be the most important factors to be aware of and consider?
- Ask unambiguously which outcomes of pelvic exenteration surgery are the most important when deciding whether to have surgery, and how each outcome would influence this decision

# Conclusion

• Final open ended question: 'Is there anything else that we haven't addressed that you think is important for patients with locally advanced or recurrent rectal cancer to be aware of or consider when deciding about whether to undergo surgery'?